William Blair has initiated protection on Denali Therapeutics Inc DNLI, an organization centered on creating medication for neurodegenerative ailments.
The analyst highlights that Denali is creating a specialised transport car (TV) platform to reinforce the supply of therapies throughout the blood-brain barrier.
It stands out from rivals with its promising potential for top-tier efficiency and scalability throughout totally different therapies and situations.
The corporate’s lead program Tividenofusp alfa, an enzyme-replacement remedy for Hunter syndrome, reveals promise as a best-in-class remedy, the analyst highlights.
William Blair has initiated with an Outperform score and a good worth of $35 per share.
The corporate has reached an settlement with the FDA on the necessities for accelerated approval and plans to submit a biologics license software in early 2025.
Insights gained from tividenofusp alfa can also simplify the event and approval course of for future therapies concentrating on different lysosomal storage ailments, resembling DNL126 for Sanfilippo syndrome sort A.
Most lately, Denali Therapeutics initiated dosing in a world BEACON Section 2a trial of BIIB122 (DNL151) for LRRK2-associated Parkinson’s illness.
Denali’s market cap stands at $2.93 billion, with an enterprise worth of $2.26 billion.
In comparison with its friends in neuroscience, uncommon ailments, and platform biotech, its valuation is decrease than some however greater than others, reflecting the power of its pipeline and know-how.
William Blair notes the potential for vital development as Denali advances its property, together with tividenofusp, which could obtain accelerated approval and precedence evaluation by late 2025.
If further medical information reduces dangers related to its TV-enabled strategy, Denali may obtain valuations much like corporations like Avidity Biosciences Inc. RNA, Ultragenyx Pharmaceutical Inc. RARE, Biogen Inc. BIIB, Alnylam Prescribed drugs, Inc.ALNY, and Ionis Prescribed drugs, Inc. IONS.
Value Motion: DNLI inventory is up 3.17% at $21.50 on the final test on Friday.
Learn Subsequent:
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
